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Summary The effects of a combination chemotherapy (CAV-PVP) consisting of cyclophosphamide, dox-
orubicin, hydrochloride (dox) and vincristine (CAV) alternating with cisplatin and etoposide (PVP) on
peripheral blood hematopoietic progenitor cells (PBHPs) were studied in five patients with small cell lung
cancer (SCLC). The kinetics of the CFU-GM levels were different during the CAV and PVP phases. None of
the five patients displayed a rebound increase in the level of peripheral blood CFU-GM during the CAV
phase. In contrast, all five patients displayed a rebound increase in peripheral blood CFU-GM levels during
the PVP phase of the alternative combination chemotherapy (3-5 weeks after the initiation of PVP regimen).
These findings indicate the optimal timing for leukapheresis to obtain PBHPs in SCLC patients which have
been treated with an alternating combination chemotherapy consisting of CAV-PVP.
Lung cancer is an increasingly common cause of death in
Japan, with -35,000 patients dying every year. Small cell
lung cancer (SCLC) accounts for 15-20% of all patients
with lung cancer. Combination chemotherapy has recently
produced a significant improvement in the treatment of
SCLC patients. However, disease-free survival at 3 years
occurs in only 5-10% of all patients with SCLC. One reason
for this poor prognosis is the development of resistance to
various types of chemotherapeutic drugs, indicating the
necessity for new modalities, including alternating non-cross-
resistant combination chemotherapy based on the theory of
Goldie and Coldman (Goldie & Coldman, 1979; Goldie et
al., 1982). Some studies have demonstrated that combination
chemotherapy (CAV-PVP) consisting of cyclophosphamide,
doxorubicin (dox), and vincristine (CAV) alternating with
cisplatin and etoposide (PVP) is superior to standard
chemotherapy, such as CAV or PVP (Evans et al., 1987;
Fukuoka et al., 1991).
Previous studies have shown that patients with lung cancer
displayed a rebound increase of the circulating level of
peripheral blood hematopoietic progenitor cells (PBHPs) fol-
lowing chemotherapy (Abram et al., 1981; Shimizu et al.,
1990). These PBHPs may be useful as an alternative source
for bone marrow stem cells in lung cancer patients treated
with marrow-ablative chemotherapy. We observed early
hematopoietic reconstitution with autotransplantation of
PBHPs following myeloablative chemotherapy in one patient
with SCLC (Mukai et al., 1990). However, the frequency of
the rebound increase of PBHPs appeared to depend upon the
specific chemotherapeutic regimen used (Shimizu et al., 1990;
Mukai et al., 1992). The rebound increase occurred most
frequently in patients who had received combination
chemotherapy with cisplatin and etoposide, while it was not
observed in patients who have received chemotherapy with
either cisplatin, mitomycin, and vindesine, or cisplatin and
mitomycin, or cisplatin alone. However, it remains unclear
whether a CAV-PVP alternating regimen, which is one of the
most effective chemotherapies for SCLC, could increase the
levels of PBHPs. In this study, we report that a CAV-PVP
alternating regimen can induce rebound increase of PBHPs
during the PVP phase, but not during the CAV phase.
Patients and methods
Patients
Five patients (all male; median age 61; range 38-72) with
histologically proven small cell lung cancer (SCLC) were
studied. Four patients had extensive disease, and one had
limited disease. Three patients had apparent bone metastasis,
but none had bone marrow metastasis. Patients initially
underwent the following studies: chest X-ray examination;
fiber-optic bronchoscopy with cytologic washing, brushing,
and biopsy; bone marrow aspiration and biopsy; bone scan;
brain CT scan; and abdominal ultrasound. None of the
patients had received previous chemotherapy and/or
radiotherapy in the 6 weeks prior to initiation of the study.
All patients gave their informed consent to participate in the
study.
Protocol ofchemotherapy and timing ofblood aspirationfor
PBHP measurement
The CAV regimen consisted of cyclophosphamide at a dose
of 800mgm2 given intravenously (IV) on day 1, dox at
50 mg m-2 IV on day 1, and vincristine at 1.4 mg m-2 (max-
imum 2.0 mg/body) IV on day 1. The PVP regimen consisted
of cisplatin at a dose of 80 mg m-2 IV on day 1 and
etoposide at 75 mg m-2/day-' IV on days 1-5. Cisplatin was
administered with 2000 ml of Ringer's lactate solution and
1000 ml of saline containing mannitol, metoclopramide,
dexamethasone and furosemide for 13 h. Each cycle was
repeated every 4 weeks. Blood samples were obtained by
venipuncture weekly after the initiation of chemotherapy.
Measurement ofcolonyforming unit-granulocyte macrophage
(CFU-GM)
We measured the numbers of CFU-GM to evaluate PBHPs.
The peripheral blood was diluted 1:1 with calcium- and
magnesium-free phosphate-buffered saline (PBS).
Mononuclear cells were separated by centrifugation using
Lymphocyte Separation Medium (LSM; Organon Teknika
Co., Durham). For the CFU-GM assay, the mononuclear
cells were plated in 35 mm Petri dishes in Dulbecco's
minimum essential medium (DMEM) supplemented with
0.8% methylcellulose, 20% foetal bovine serum (FBS), 1%
bovine serum albumin (BSA), and 100Uml-' of purified
granulocyte macrophage-colony-stimulating factor (GM-
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CSF, Chugai Co., Tokyo) at 5 x 105 per plate, and cultured
in a humidified incubator at 37°C and 5% CO2. Duplicate
cultures were set up, and colonies (>40 cells) were scored
under an inverted microscope after incubation for 14 days.
The number of CFU-GM was calculated as the total number
of colonies per ml of blood.
Results
When mononuclear cells were stimulated with GM-CSF in
vitro, the average number ± standard deviation (SD) of
CFU-GM per ml of peripheral blood in five patients with
SCLC was 38.2 ± 24.8 before chemotherapy. There was a
considerable variation in the CFU-GM levels between indi-
viduals before initiation of chemotherapy.
Figure 1 shows the effects of the CAV-PVP regimen on
CFU-GM from the peripheral blood in patients with SCLC.
After initiation of chemotherapy, the levels of CFU-GM in
the peripheral blood were markedly decreased after 1 week
but, although they recovered to pretreatment levels for the
next 2-3 weeks, they did not display a rebound increase
during the CAV phase of alternative chemotherapy. The
levels of CFU-GM in the peripheral blood decreased
markedly again 1 week after initiation of the PVP phase. The
levels of CFU-GM in the peripheral blood recovered to
pretreatment levels within 2 weeks, markedly increased for
the next 1-3 weeks, and then decreased 5-6 weeks after the
initiation of the PVP phase. CFU-GM levels at 1 (P<0.01),
5 (P<0.05), and 10 (P<0.05) weeks after initiation of
chemotherapy were significantly lower, but the CFU-GM
level at 8 weeks (P<0.05) after initiation of chemotherapy
was significantly higher than that before chemotherapy in a
paired t-test.
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Figure 1 The kinetics of the CFU-GM response in peripheral
blood following CAV-PVP alternating combination
chemotherapy in five patients. Peripheral blood CFU-GM was
evaluated every week after initiation of chemotherapy. The
chemotherapeutic regimen consisted of a CAV phase consisting
of cyclophosphamide at a dose of 800 mg m-2 given int-
ravenously (IV) on day 1, doxorubicin at 50mg m-2 IV on day 1,
vincristine at 1.4mgm-2 IV (maximum 2.0mg/body) on day 1,
and a PVP phase consisting of cisplatin at 80 mg m-2 IV on day
29 and etoposide at 75 mg/m2/day IV on days 29-33. The level
of CFU-GM was calculated as the total number of colonies per
ml of peripheral blood samples in the presence of GM-CSF. Each
point indicates the mean of duplicate experiments.
Discussion
In this study, we examined the effect of a CAV-PVP alter-
nating combination chemotherapy on hematopoietic pro-
genitor cells in the peripheral blood of patients with SCLC.
After initiation of each phase of chemotherapy, the levels of
CFU-GM in the peripheral blood markedly decreased within
1 week, and displayed a rebound increase 3-5 weeks after
initiation of the PVP phase of chemotherapy, but not during
the CAV phase of chemotherapy. It is possible that the order
in which the chemotherapy is administered, rather than the
type of therapy, influences the degree of mobilisation of
progenitor cells. However, we have previously shown that a
PVP regimen induced the rebound increase of PBHPs more
effectively than several other chemotherapy regimens
(Shimizu et al., 1990). Furthermore, in another study we
found that the number of mobilised progenitor cells declines
rapidly as chemotherapy is repeated; the cell yield from
apheresis after a second course of chemotherapy was -30%
of that after the initial course of chemotherapy (Takaue et
al., 1992). Considering these data, it is unlikely that the
order, rather than the type, of chemotherapy produces the
increase in progenitor cells.
The magnitude of the increase in the number of progenitor
cells observed in this study appears to be modest compared
to other published data, and we currently have no definitive
explanation for this difference. In 13 patients with lymphoma
or breast cancer, Tarella et al. (1991) reported that the
minimum increase in the number of blood CFU-GM was
1200 ml-'. However, they used a therapy which included
high-dose cyclophosphamide (7 gm-2) for mobilisation. It
has been reported that a higher dose is required for cyclo-
phosphamide to produce a satisfactory mobilisation effect
(To et al., 1990; Kotasek et al., 1992). In patients with
ovarian cancer, a regimen including cisplatin 200 mg m-2 and
cyclophosphamide 1.5 gm-2 induced roughly the same in-
crease in progenitor cells as in our present study (Menichella
et al., 1991). Hence, the disorders of the patients included in
the study and/or the specific chemotherapy regimen
administered may have an effect on subsequent progenitor
mobilisation.
In addition, the differences between the methods used for
blood progenitor assay should be carefully tested. The
growth characteristics of hematopoietic progenitor cells
obtained from the peripheral blood are different from those
of bone marrow progenitors (Caracciolo et al., 1989; Takaue
et al., 1990). Blood progenitor is less supported by the
recombinant product of G-CSF or GM-CSF, and
interleukin-3 (IL-3) is required for optimal growth (Takaue et
al., 1990). Hence, a study which included a potent super-
natant of cultured cells or recombinant products of IL-3 or
interleukin-6 as a source of colony-stimulating activities may
yield more colonies than those which use recombinant G-
CSF or GM-CSF. In any event, a carefully designed prospec-
tive study and sequential evaluation of CD34 + cells, rather
than CFU-GM, in the peripheral blood may answer these
questions (Siena et al., 1991).
A great deal of attention has recently been focused on
PBHPs as an alternative to bone marrow transplantation
following ablative chemotherapy (Henon et al., 1991; Kess-
inger & Armitage, 1991; Gale et al., 1992; Korbling et al.,
1992). The advantages of PBHPs are that they can be
obtained without the use of anesthesia and without the dis-
comfort involved in multiple bone marrow aspiration.
Moreover, PBHPs may be less likely to be contaminated by
tumour cells. Harvesting of PBHPs is usually performed 3-4
weeks following conventional chemotherapy when the
rebound increase in progenitor cells has been documented in
the peripheral blood. However, these increases depend upon
the specific chemotherapeutic regimen used. The present
study showed that PBHPs should be harvested 3-5 weeks
after the initiation of the PVP phase of chemotherapy, rather
than during the CAV phase.
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